This Expert Review features an expert discussion and downloadable slides focusing on the role of PARP inhibitors in breast cancer, including mechanism of action, emerging clinical data and ongoing trials in the early and metastatic settings, and patient selection for treatment.
Oct 19, 2017
Oct 19, 2018
Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
University of Sheffield
Weston Park Hospital
Sheffield, United Kingdom
Joyce O’Shaughnessy, MDBaylor University Medical Center
Dallas, Texas, United States
- PARP inhibitors mechanism of action
- Rationale for PARP inhibition in breast cancer
- Patient selection
- PARP inhibitors in metastatic breast cancer
- PARP inhibitors in early breast cancer
- Clinical implications
This educational activity is designed for surgical, radiation, and medical oncologists, and other healthcare providers involved in the management of patients with breast cancer.
Upon completion of this educational activity, participants should be able to:
- Describe the impact of BRCA 1/2 testing on clinical outcomes for patients with breast cancer
- Assess recent and ongoing clinical trial data of PARP inhibitors in patients with breast cancer
- Select optimal treatment options, based on current treatment guidelines and emerging clinical trial data, for patients with triple-negative and BRCA-mutated breast cancer
This educational activity is supported by a grant from AstraZeneca.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.